The US company Immusoft has dosed the first subject with its investigational engineered B cell therapy, ISP-001, in a human Phase I clinical trial of mucopolysaccharidosis type I (MPS I).
The EU-funded AiChemist project aims to provide advanced AI approaches with increased explainability and broad applicability. It brings together key players from academia and industry and includes a structured training program for AI specialists.
‘Valuable insights, trusting atmosphere and great people’ was how a participant summed up her experience of the two-day workshop hosted by Ascenion exclusively for colleagues from its partner institutes, universities and clinics.
The partners have initiated a phase I trial to evaluate LuCaFab (ITM-31), a radiolabelled a-CA XII antibody Fab fragment, for the treatment of glioblastoma. The goal is to eradicate residual tumour cells following surgery to reduce the risk of relapse.
Ascenion is looking forward to a reunion with industry decision makers, venture capitalists, academic inventors and entrepreneurs. Eight from a total of 56 projects to be featured originate from Ascenion’s academic partners.
TANGO Therapeutics will employ two CRISPR technologies invented by Ulrich Elling at IMBA and in part by Krzysztof Chylinski at VBCF to discover genes involved in tumourigenesis and immune evasion as targets for next-generation therapies.
Supported by Ascenion, Felix Krenzien and his team at Charité – Universitätsmedizin Berlin attracted the grant from the Else Kröner-Fresenius-Stiftung (EKFS) to translate their new approach for quantifying extracellular NAD+ into medical practice.
Pharma-backed incubator INCATE selected the HZI start-up project Myxobiotics as one of the first start-ups to get support. Myxobiotics develops a new class of antibiotics against Acinetobacter baumannii, which causes severe, difficult-to-treat respiratory infections.
Supported by Ascenion, Matthias Bruhn and his team at TWINCORE - Centre for Experimental and Clinicial Infection Research have attracted EUR 97,000 to explore the commercial feasibility of their MEMUMAB project. The goal is to provide therapeutic antibodies against infectious diseases such as COVID-19.
The German Federal Ministry of Education and Research (BMBF) is providing EUR 6.5 million in funding for 10 selected research projects targeting long-term symptoms of COVID-19. Ascenion’s partner institutes are making significant contributions to three of these projects.
The method, SARSeq (Saliva Analysis by RNA sequencing), enables highly sensitive, massively-parallel and cost-effective testing for SARS-CoV-2. Ascenion has supported its patent protection and licencing for commercial use in China.
The HIOH pursues an integrative approach to understanding the emergence of new pathogens and developing suitable intervention mechanisms. Ascenion is its technology transfer partner.
Scientists from the Helmholtz Institute for RNA-based Infection Research (HIRI) and the Julius Maximilian University (JMU) in Würzburg have paved the way for a new diagnostic platform that enables the detection of multiple markers in one single test.
Heidelberg Pharma AG is allowed to initiate a Phase I/IIa clinical study in the US to evaluate the dosing, safety and anti-tumour efficacy of its lead candidate HDP-101 in multiple myeloma.
Ascenion, technology transfer partner of Hannover Medical School (MHH), has supported the conclusion of a collaboration and licence agreement between MHH and Novo Nordisk.
An innovative approach to combat infections caused by Staphylococcus aureus will receive funding of initially 1.33 million USD plus an additional 7.44 million USD, depending on project progress. It is jointly developed by the HZI and the LDC.
Ascenion will support eight members and four partners of the Innovative Training Network (ITN) ‘SMABEYOND’ in all aspects relating to the intellectual property and potential commercialization of their work.
The TransferAllianz proposes 5 measures to leverage the innovation potential of academic research and drive sustainable economic recovery following the corona crisis.
Diffratec, a spin-off from the Medical University of Innsbruck (MUI), commercializes breakthrough diffractive elements. These elements, in particular Moiré lenses, are extremely compact and tunable with high speed and precision.
Formula Pharmaceuticals, a partner of the Max Delbrück Center for Molecular Medicine (MDC) has merged with cell therapy specialist CoImmune, with CoImmune as the surviving company. The new entity will continue its strategic partnership with the MDC.
A research team at the German Center for Neurodegenerative Diseases (DZNE) has received the ‘Hugo Junkers Award for Research and Innovation from Saxony-Anhalt 2019’.
Ascenion GmbH, technology transfer partner of the Max Delbrück Center for Molecular Medicine (MDC), has supported the conclusion of an agreement between the MDC and Fate Therapeutics, Inc.
Agreement with Max Delbrück Center Provides Access to Broad Intellectual Property Portfolio of Unique Humanized Antibody Fragments and Antigen-Binding…
Amgen announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for BLINCYTO® (blinatumomab) for the treatment…
A consortium of nine partners from five European countries, led by the Helmholtz Zentrum München, will work together with a transdisciplinary approach…
Berlin Cures, one of Ascenion’s investment portfolio companies, has announced the start of a clinical trial with its lead candidate BC007. The Phase I…
BigChem GmbH was founded this October to commercialize validated IT products and services developed at the Helmholtz Zentrum München. The research was…